Compare Adaptive Biotechnologies Corp (ADPT) vs Synchrony Financial (SYF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Synchrony Financial — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Synchrony Financial trades at $71.92 (market cap $25.40B). The key difference: Synchrony Financial is far larger — about 7.6× Adaptive Biotechnologies Corp's market cap, and Synchrony Financial pays a 1.59% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SYF | |
|---|---|---|
Market Cap | $3.33B | $25.40B |
Sector | Health | Financials |
52-Week High | $22.37 | $88.47 |
52-Week Low | $10.24 | $63.78 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SYF trades at $77.05, up 0.94% today, with a bullish technical outlook supported by moving averages and key resistance at $78. The stock shows strong fundamentals with a P/E of 7.98, net income margin of 24.06%, and consistent earnings beats in recent quarters. Recent news highlights executive changes and partnership expansions, reinforcing growth initiatives.
The outlook remains positive with a consensus price target of $85, representing ~10% upside. Risks include interest rate sensitivity and competitive pressures, but strong analyst buy ratings (62.5%) and robust cash flow support a favorable investment case for value-oriented investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
